Is there no prescription? Reputation in the pharmaceutical industry

Andrea Fischer
Additional contact information
Andrea Fischer: Former German Federal Health Minister

A chapter in Reputation Capital, 2009, pp 347-359 from Springer

Abstract: Abstract The reputation of the pharmaceutical industry is at best contradictory. Despite the undeniable benefits it brings by developing new medicines, its profit orientation and relatively high profit margins are viewed with mistrust. This is underscored by sporadic reports about sometimes dubious practices with risky consequences for patients and real health improvements. The industry can only confront this with a long-term strategy built on more openness and a greater readiness to face public debate. This readiness must be demonstrated by both a visible corporate strategy – that must be implemented right through to the lowest level of staff – and in the way the industry deals with increasing calls from the public for greater transparency.

Keywords: Pharmaceutical Industry; Poor Country; High Profit Margin; Approval Agency; Risky Consequence (search for similar items in EconPapers)
Date: 2009
References: Add references at CitEc
Citations: View citations in EconPapers (1)

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-642-01630-1_24

Ordering information: This item can be ordered from
http://www.springer.com/9783642016301

DOI: 10.1007/978-3-642-01630-1_24

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().